Elsevier

The Lancet

Volume 387, Issue 10037, 18–24 June 2016, Pages 2486-2487
The Lancet

Comment
WHO recommendations on shorter treatment of multidrug-resistant tuberculosis

https://doi.org/10.1016/S0140-6736(16)30729-2Get rights and content

References (14)

There are more references available in the full text version of this article.

Cited by (49)

  • Outcomes and adherence of shorter MDR TB regimen in patients with multidrug resistant tuberculosis

    2023, Indian Journal of Tuberculosis
    Citation Excerpt :

    In 2016, WHO guidelines conditionally recommended a shorter 9–12-month MDR-TB regimen for patients meeting specific criteria, based on results of a systematic review and individual patient data meta-analysis.3,4 However, uncertainty remains about the regimen's effectiveness in the presence of resistance to constituent drugs, including fluoroquinolones, ethambutol, pyrazinamide and prothionamide.5–9 To study adherence and treatment outcome of shorter MDR TB regimen in patients with MDR-TB.

  • Simultaneous determination of the potent anti-tuberculosis regimen—Pyrazinamide, ethambutol, protionamide, clofazimine in beagle dog plasma using LC–MS/MS method coupled with 96-well format plate

    2019, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    Some researches have uncovered the synergism activity among CFZ and other anti-TB drugs, especially co-administrated with EMB and PZA [19,20]. The treatment guidelines for drug-resistant TB of WHO in 2016 highlighted the capacity of CFZ and the CFZ-contained regimen (including PZA, EMB, PTO, CFZ, kanamycin acid and isoniazid) for MDR-TB patients for the shorter treatment course, low cost and accessibility [18]. One most effective regimen containing these four compounds for MDR-TB patients with a minimum period of nine-month treatment has been validated for naive MDR-TB patients by a clinical trial in Bangladesh from 1997 to 2007 [21].

  • Vicinal Diaryl Pyrazole: A Therapeutically Potential Molecular Scaffold

    2018, Vicinal Diaryl Substituted Heterocycles: A Gold Mine for the Discovery of Novel Therapeutic Agents
View all citing articles on Scopus
View full text